This notion is supported by recent studies showing a potential clinical benefit of selective genetic targeting of GSK-3α over GSK-3β, which inhibited AML progression [60] and myeloid transformation [64] without affecting β-catenin. The gene discussed is GSK3B; the disease is acute myeloid leukemia.